Abera Bioscience PEG

Mitä Abera Bioscience tekee? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience on yksi Eurpooliin suosituimmista yhtiöistä.